GeoVax and Sino Biological establish exclusive supply agreement for research grade bioreagents related to SARS-CoV-2 (COVID-19) vaccine development

GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that Beijing- and Philadelphia-based Sino Biological, Inc. will be its exclusive supplier of SARS-CoV-2 (COVID-19) bioreagent research products.

Under the terms of the agreement, Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax. Sino Biological will also obtain exclusive rights to research-use-only (RUO) reagents developed jointly by the companies. Financial terms were not disclosed. Sino Biological was the first to market with mammalian cell-made COVID-19 viral recombinant proteins and offers a full range of these and other bioreagents to complement and aid in COVID-19 vaccine development and has the world’s largest selection of coronavirus research-grade products. GeoVax is at the forefront of development for a COVID-19 vaccine and its use of recombinant viruses to generate virus-like particles (VLPs) in vivo has demonstrated considerable immune response for other viruses in a number of human clinical trials.

Commenting on the exclusive partnership, David A. Dodd, GeoVax Chairman & CEO stated, “We are delighted to establish this collaboration with Sino Biological related to our COVID-19 vaccine development program. Sino Biological is recognized as the research reagent industry leader in developing and providing COVID-19 bioreagent research products, as well as a leader throughout the bioreagent research industry. We look forward to further expansion of our relationship with Sino Biological, including our agreement related to research-use-only (RUO) reagents.”

GeoVax’s unique VLP-generation technology is exciting, and its commitment to the development of a vaccine for COVID-19 is inspiring. We at Sino Biological are honored to be the exclusive provider of COVID-19-related research reagents to assist their vaccine development efforts.”

Rob Burgess, Ph.D., Chief Business Officer, Sino Biological

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2020, May 06). GeoVax and Sino Biological establish exclusive supply agreement for research grade bioreagents related to SARS-CoV-2 (COVID-19) vaccine development. News-Medical. Retrieved on July 12, 2020 from https://www.news-medical.net/news/20200506/GeoVax-and-Sino-Biological-establish-exclusive-supply-agreement-for-research-grade-bioreagents-related-to-SARS-CoV-2-(COVID-19)-vaccine-development.aspx.

  • MLA

    Sino Biological Inc.. "GeoVax and Sino Biological establish exclusive supply agreement for research grade bioreagents related to SARS-CoV-2 (COVID-19) vaccine development". News-Medical. 12 July 2020. <https://www.news-medical.net/news/20200506/GeoVax-and-Sino-Biological-establish-exclusive-supply-agreement-for-research-grade-bioreagents-related-to-SARS-CoV-2-(COVID-19)-vaccine-development.aspx>.

  • Chicago

    Sino Biological Inc.. "GeoVax and Sino Biological establish exclusive supply agreement for research grade bioreagents related to SARS-CoV-2 (COVID-19) vaccine development". News-Medical. https://www.news-medical.net/news/20200506/GeoVax-and-Sino-Biological-establish-exclusive-supply-agreement-for-research-grade-bioreagents-related-to-SARS-CoV-2-(COVID-19)-vaccine-development.aspx. (accessed July 12, 2020).

  • Harvard

    Sino Biological Inc.. 2020. GeoVax and Sino Biological establish exclusive supply agreement for research grade bioreagents related to SARS-CoV-2 (COVID-19) vaccine development. News-Medical, viewed 12 July 2020, https://www.news-medical.net/news/20200506/GeoVax-and-Sino-Biological-establish-exclusive-supply-agreement-for-research-grade-bioreagents-related-to-SARS-CoV-2-(COVID-19)-vaccine-development.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.